ethyl 4-[[2-(4-chlorophenyl)phenyl]methyl]-1-[4-[[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylcarbamoyl]phenyl]piperidine-4-carboxylate | 1616557-77-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 4-[[2-(4-chlorophenyl)phenyl]methyl]-1-[4-[[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylcarbamoyl]phenyl]piperidine-4-carboxylate
• CAS: 1616557-77-7
• 化学式: C₄₉H₅₂ClF₃N₄O₈S₃
• 分子量: 1013.62
• InChiKey: KMPPJGOVTXGJFJ-LDLOPFEMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.5
• 重原子数：
  68
• 可旋转键数：
  19
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  194
• 氢给体数：
  2
• 氢受体数：
  15

反应信息

• 作为产物：
  描述：

  对氟苯甲酸乙酯 在 4-二甲氨基吡啶 、 四甲基乙二胺 、 sodium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 、 甲苯 为溶剂， 生成 ethyl 4-[[2-(4-chlorophenyl)phenyl]methyl]-1-[4-[[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylcarbamoyl]phenyl]piperidine-4-carboxylate
  参考文献：
  名称：

  Towards the next generation of dual Bcl-2/Bcl-xL inhibitors

  摘要：

  Structural modifications of the left-hand side of compound 1 were identified which retained or improved potent binding to Bcl-2 and Bcl-x(L) in in vitro biochemical assays and had strong activity in an RS4;11 apoptotic cellular assay. For example, sulfoxide diastereomer 13 maintained good binding affinity and comparable cellular potency to 1 while improving aqueous solubility. The corresponding diastereomer (14) was significantly less potent in the cell, and docking studies suggest that this is due to a stereochemical preference for the R-S versus S-S sulfoxide. Appending a dimethylaminoethoxy side chain (27) adjacent to the benzylic position of the biphenyl moiety of 1 improved cellular activity by approximately threefold, and this activity was corroborated in cell lines overexpressing Bcl-2 and Bcl-x(L). (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.036

文献信息

• Towards the next generation of dual Bcl-2/Bcl-xL inhibitors
  作者：Jeffrey G. Varnes、Thomas Gero、Shan Huang、R. Bruce Diebold、Claude Ogoe、Paul T. Grover、Mei Su、Prasenjit Mukherjee、Jamal Carlos Saeh、Terry MacIntyre、Galina Repik、Keith Dillman、Kate Byth、Daniel John Russell、Stephanos Ioannidis

  DOI：10.1016/j.bmcl.2014.05.036

  日期：2014.7

  Structural modifications of the left-hand side of compound 1 were identified which retained or improved potent binding to Bcl-2 and Bcl-x(L) in in vitro biochemical assays and had strong activity in an RS4;11 apoptotic cellular assay. For example, sulfoxide diastereomer 13 maintained good binding affinity and comparable cellular potency to 1 while improving aqueous solubility. The corresponding diastereomer (14) was significantly less potent in the cell, and docking studies suggest that this is due to a stereochemical preference for the R-S versus S-S sulfoxide. Appending a dimethylaminoethoxy side chain (27) adjacent to the benzylic position of the biphenyl moiety of 1 improved cellular activity by approximately threefold, and this activity was corroborated in cell lines overexpressing Bcl-2 and Bcl-x(L). (C) 2014 Elsevier Ltd. All rights reserved.